Aura Biosciences, Inc. (NASDAQ:AURA) Insider Janet Jill Hopkins Sells 11,822 Shares

Aura Biosciences, Inc. (NASDAQ:AURA) insider Janet Jill Hopkins sold 11,822 shares of the firm’s stock in a transaction dated Monday, November 18th. The shares were sold at an average price of $9.36, for a total transaction of $110,653.92. Following the transaction, the insider now directly owns 151,693 shares in the company, valued at approximately $1,419,846.48. The trade was a 7.23 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this link.

Aura Biosciences Price Performance

Shares of Aura Biosciences stock opened at $9.14 on Tuesday. The firm has a market cap of $456.54 million, a P/E ratio of -5.28 and a beta of 0.33. Aura Biosciences, Inc. has a fifty-two week low of $6.63 and a fifty-two week high of $12.38. The firm has a 50 day simple moving average of $9.82 and a 200 day simple moving average of $8.54.

Aura Biosciences (NASDAQ:AURA) last released its quarterly earnings data on Tuesday, November 12th. The company reported ($0.42) EPS for the quarter, beating analysts’ consensus estimates of ($0.44) by $0.02. On average, sell-side analysts expect that Aura Biosciences, Inc. will post -1.69 EPS for the current year.

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on the stock. Lifesci Capital raised shares of Aura Biosciences to a “strong-buy” rating in a research note on Monday, September 9th. Scotiabank increased their price target on shares of Aura Biosciences from $20.00 to $23.00 and gave the stock a “sector outperform” rating in a research report on Friday, October 18th. Cowen restated a “buy” rating on shares of Aura Biosciences in a research note on Friday, October 18th. Evercore ISI upgraded shares of Aura Biosciences to a “strong-buy” rating in a research note on Monday, September 16th. Finally, HC Wainwright reissued a “buy” rating and set a $22.00 price objective on shares of Aura Biosciences in a report on Thursday, November 14th. Five equities research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. According to MarketBeat.com, Aura Biosciences currently has an average rating of “Buy” and a consensus target price of $23.00.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of the company. American Century Companies Inc. bought a new stake in Aura Biosciences during the second quarter worth about $119,000. American International Group Inc. boosted its position in Aura Biosciences by 27.4% during the first quarter. American International Group Inc. now owns 17,579 shares of the company’s stock worth $138,000 after purchasing an additional 3,782 shares during the period. Virtu Financial LLC bought a new stake in shares of Aura Biosciences during the 1st quarter worth about $144,000. SG Americas Securities LLC acquired a new position in shares of Aura Biosciences in the third quarter valued at approximately $169,000. Finally, Rhumbline Advisers grew its holdings in Aura Biosciences by 39.6% in the 2nd quarter. Rhumbline Advisers now owns 63,483 shares of the company’s stock valued at $480,000 after buying an additional 18,011 shares in the last quarter. 96.75% of the stock is currently owned by institutional investors.

Aura Biosciences Company Profile

Aura Biosciences, Inc, a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates.